(MENAFN- GlobeNewsWire - Nasdaq) With unprecedented advancements in technology and personalized medicine, the North America organoids and spheroids market is revolutionizing biomedical research, enabling tailored therapeutics, and fundamentally reshaping drug discovery methodologies, thus paving the way for a new era in healthcare.New Delhi, Dec. 19, 2024 (GLOBE NEWSWIRE) -- According to the latest Astute Analytica research, the North America organoids and spheroids market is projected to hit the market valuation of US$ 3,878.74 million by 2033 from US$ 667.25 million in 2024 at a CAGR of 21.6% during the forecast period 2025–2033.
The organoids and spheroids market in North America is on the cusp of significant expansion, driven by technological advancements and growing recognition of their potential in biomedical research and clinical applications. The increasing demand for more accurate and physiologically relevant models in drug discovery and personalized medicine is propelling the adoption of organoid and spheroid technologies. In 2023, the U.S. National Cancer Institute (NCI) allocated funding for 20 new organoid-based cancer research projects, highlighting the region's focus on advancing cancer therapeutics through innovative models.
Request Sample Copy @
Innovations such as the development of multi-organ organoids and organ-on-a-chip platforms are enhancing the capabilities of these models, enabling the study of complex inter-organ interactions and systemic diseases. For example, in 2023, a Canadian research team successfully developed a gut-liver organoid platform to study metabolic disorders, which has already been adopted by five pharmaceutical companies for drug metabolism studies. Collaborative efforts between academia, industry, and government agencies are fostering an environment conducive to innovation and commercialization. Additionally, four North American biotech startups launched partnerships with global pharmaceutical giants in 2023 to co-develop organoid-based therapeutic solutions for neurodegenerative diseases.
Future opportunities in the organoids and spheroids market market are abundant, particularly in the areas of regenerative medicine and personalized therapeutics. The potential to grow patient-specific tissues and organs opens new horizons for treating organ failure and complex diseases. In 2023, three clinical trials were initiated in the U.S. to test organoid-derived cell therapy for liver and kidney repair. Moreover, the integration of artificial intelligence and machine learning with organoid research is expected to enhance data analysis and accelerate discoveries. A recent collaboration between a leading AI firm and a Boston-based biotech company aims to use AI algorithms to analyze 10 million organoid datasets for drug discovery, showcasing the potential for technology-driven advancements in the sector. As regulatory frameworks adapt, the North American organoids and spheroids market is poised for substantial growth, with the promise of transforming healthcare outcomes and establishing new standards in medical research and treatment.
Key Findings in North America Organoids and Spheroids Market
| Market Forecast (2033) | US$ 3,878.74 million |
| CAGR | 21.6% |
| By Type | Spheroids (52.6%) |
| By Method | Spheroids (52.7%) |
| By Application | Developmental Biology (32.0%) |
| By End Users | Biotechnology and Pharmaceutical Companies (45.7%) |
| By Source | Spheroids (55.6%) |
| Top Drivers | Rising need for personalized medicine enhances patient-specific treatment and disease modeling approaches. Advancements in 3D cell culture technologies improve research and development efficiency significantly. Growing disease prevalence necessitates superior models for effective drug discovery efforts worldwide. |
| Top Trends | Integration of organoids in high-throughput screening accelerates drug discovery and testing processes. Development of multi-organ organoids models complex tissue interactions for disease studies worldwide. Growing adoption in cancer research for studying tumor biology and drug responses effectively. |
| Top Challenges | Integration of organoids in high-throughput screening accelerates drug discovery and testing processes. Development of multi-organ organoids models complex tissue interactions for disease studies worldwide. Growing adoption in cancer research for studying tumor biology and drug responses effectively. |
Spheroids to Control Over 52% Revenue Share of the North America's Market
The dominance of spheroids in North America's organoids and spheroids market is deeply rooted in their adaptability to a wide range of research environments and their ability to streamline experimental workflows. Unlike organoids, which often require organ-specific growth factors, spheroids are more flexible and can be cultured using standard cell culture techniques. In 2023, over 4,000 studies globally utilized spheroids, with North America contributing to nearly half of these publications. Furthermore, spheroids are widely used in oncology, where over 1,500 tumor spheroid models were developed in North America alone to study cancer progression and metastasis.
Another factor driving the popularity of spheroids is their compatibility with cutting-edge technological advancements. For instance, over 200 research facilities in North America have adopted automated microfluidic platforms specifically designed to produce uniform spheroids. These platforms enable high-throughput production of spheroid models, facilitating large-scale drug screening. In addition, the ability of spheroids to integrate seamlessly with advanced imaging systems has been a game-changer; over 500 labs now use spheroid-based assays in combination with 3D imaging technologies for detailed analysis of cellular interactions and drug responses. These technological advantages have cemented spheroids as a preferred choice for researchers.
Developmental Biology to Remain the Largest Applications, Poised to Control Over 32% Market Share
Organoids and spheroids market are transforming developmental biology in North America by offering insights into cellular communication and organogenesis that were previously unattainable. While organoids are often celebrated for their organ-specific architecture, spheroids have emerged as versatile models for studying cellular environments. In 2023, over 1,200 papers cited the use of spheroid models in developmental biology research in North America. Spheroids like embryoid bodies, derived from pluripotent stem cells, have been instrumental in understanding early-stage embryonic development, allowing researchers to identify over 20 previously unknown cellular pathways involved in tissue formation.
One of the key reasons for the adoption of spheroids in developmental biology in the North America organoids and spheroids market is their straightforward scalability, making them ideal for studying cellular processes in larger sample sizes. Over 400 labs in North America now routinely use spheroid cultures to study cell differentiation and tissue regeneration. Additionally, spheroids are widely utilized in regenerative medicine projects, with over 100 new grants awarded in 2023 for studies focusing on spheroid-based tissue engineering. The ease of manipulation and high reproducibility of spheroids make them indispensable tools for developmental biology applications, accelerating breakthroughs in understanding human biology.
Biotechnology and Pharmaceutical Companies are Set to Continue Being the largest End Users of Organoids and Spheroids, Expected to Contribute over 45% Market Revenue
Biotechnology and pharmaceutical companies are increasingly turning to spheroids and organoids due to their ability to improve preclinical drug development workflows. In North America organoids and spheroids market, over 10,000 preclinical experiments annually now incorporate spheroid-based assays, with tumor spheroids being the most widely used. These models have been particularly effective in mimicking the tumor microenvironment, leading to the discovery of over 50 novel cancer drug candidates in the last three years. Such breakthroughs have made spheroids indispensable in oncology drug pipelines, with over 300 biotech firms in the U.S. integrating spheroid models into their workflows.
Pharmaceutical companies are also leveraging spheroids for their ability to reduce reliance on animal testing while improving predictive accuracy for human trials. Over 200 North American companies have reported shorter preclinical timelines-by an average of four months-when using spheroids for toxicity testing and drug efficacy studies. In 2023, 15 newly approved drugs in the U.S. were tested using spheroid models during their preclinical phases, highlighting their growing significance. The ability of spheroids to mimic a wide range of human tissues has also led to their use in over 1,000 personalized medicine studies in North America, further driving their adoption across the industry.
Ask For Customization @
Spheroids are the Most Dominant and Lucrative Source In North America Organoids and Spheroids Market
Spheroids derived from various sources, particularly primary cells, are leading the North American organoids and spheroids market due to their ability to replicate patient-specific conditions. In 2023, over 700 studies in North America utilized primary cell-derived spheroids for personalized drug testing, enabling researchers to identify over 100 unique patient-specific drug responses. These spheroids have shown exceptional promise in modeling diseases such as liver fibrosis and chronic kidney disease, where patient-derived cells provide unparalleled physiological relevance. Additionally, the number of studies employing primary cell-derived spheroids has tripled in the last five years, indicating their growing prominence.
iPSC-derived spheroids are also making significant strides in the organoids and spheroids market, particularly in regenerative medicine and genetic disease modeling. In 2023, over 300 North American labs used iPSC-derived spheroids to study disorders like Parkinson's, ALS, and cystic fibrosis. These spheroids allow researchers to simulate disease progression in a controlled environment, leading to the identification of over 30 new therapeutic targets in the past year alone. Moreover, the advancement of CRISPR-based gene-editing technologies has made it possible to modify iPSC-derived spheroids for specific research needs, with over 150 labs in North America adopting this approach in 2023. The versatility and precision of these models ensure their continued dominance in the market.
North America Organoids and Spheroids Market Key Players:
3D BioMatrix 3D Biotek LLC ATCC Corning Incorporated InSphero/Perkin Elmer Lonza Prellis Biologics Stem Cell Technologies Thermo Fisher Scientific Cherry Biotech Other Prominent Players
Key Segmentation
:
By Type
Organoids Neural Organoids Hepatic Organoids Intestinal Organoids Other Organoids
Spheroids Multicellular tumor spheroids (MCTS) Neurospheres Mammospheres Hepatospheres Embryoid bodies
By Method
Organoids General Submerged Method for Organoid Culture Crypt Organoid Culture Techniques Air Liquid Interface (ALI) Method for Organoid Culture Clonal Organoids from Lgr5+ Cells Brain and Retina Organoid Formation Protocol
Spheroids Micropatterned Plates Low Cell Attachment Plates Hanging Drop Method Others
By Source
Organoids Primary Tissues Stem Cells
Spheroids Cell Line Primary Cell iPSCs Derived Cell
By Application
Developmental Biology Personalized Medicine Regenerative Medicine Disease Pathology Studies Drug Toxicity & Efficacy Testing
By End Use
Biotechnology and pharmaceutical industries Academic & Research Institutes Hospitals and diagnostic centers
By North America
Inquire more about this report before purchase:
About Astute Analytica
Astute Analytica is a global analytics and advisory company which has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in depth and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the Globe. They are able to make well calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising of business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of best cost-effective, value-added package from us, should you decide to engage with us.
Contact Us:
Astute Analytica
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
For Sales Enquiries: ...
Website:
LinkedIn | Twitter | YouTube
CONTACT: Contact Us:
Astute Analytica
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
For Sales Enquiries: ...
Website:
MENAFN19122024004107003653ID1109012826
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.